| Name | Buflomedil hydrochloride |
| Description | Buflomedil hydrochloride (Fonzylane), a vasodilator, is used in therapy of claudication or the symptoms of the peripheral arterial disease. |
| In vitro | Buflomedil enhances intracellular cAMP levels in human keratinocytes, either secondary to adenyl-cyclase stimulation (BC) or phosphodiesterase inhibition (PTX). Buflomedil diminishes release of TPA-induced TNF-alpha and IL-8 in keratinocytes; in the case of IL-8, this inhibition may occur to transcriptional level. At the micromolar level, Buflomedil notably inhibits epinephrine-induced aggregation. Buflomedil leads to a weak inhibition of collagen- and ADP-induced aggregation. Buflomedil inhibits grainy secretion and the interaction of fibrinogen with its receptor on platelet. the capillary perfusion is improved by Buflomedil hypochloride in such related situations, evoking a possible effect upon neutrophils. Buflomedil Completely inhibits adhesion of histamine related neutrophil (flow system) and partially inhibits adhesion after IL-1-4 hours (flow and stable systems). Buflomedil lowers the hypoxia-induced neutrophil adhesion and expression of P-selectin at the surface of endothelial cells. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 7 mg/mL (20.36 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.82 mM), Sonication is recommended.
H2O : 63 mg/mL (183.22 mM), Sonication is recommended.
DMSO : 50 mg/mL (145.41 mM), Sonication is recommended.
|
| Keywords | α-adrenergic receptor | Inhibitor | inhibit | Buflomedil hydrochloride | Buflomedil | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Trifluoperazine dihydrochloride | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Tolazoline hydrochloride | Dexmedetomidine hydrochloride | Isoprenaline hydrochloride | D-Mannitol | Mianserin hydrochloride | Trazodone hydrochloride | Atenolol | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Toxic Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
